copaxone stungulyf, lausn í áfylltri sprautu 40 mg/ml
teva gmbh - glatiramer acetat - stungulyf, lausn í áfylltri sprautu - 40 mg/ml
copaxone stungulyf, lausn í áfylltri sprautu 20 mg/ml
teva gmbh - glatiramer acetat - stungulyf, lausn í áfylltri sprautu - 20 mg/ml
alutard sq (betula verrucosa) stungulyf, dreifa
alk-abelló a/s - betula verrucosa - stungulyf, dreifa
alutard sq (cat hair) stungulyf, dreifa
alk-abelló a/s - kattahár - stungulyf, dreifa
alutard sq (dermatophagoides pteronyssinus) stungulyf, dreifa
alk-abelló a/s - dermatophagoides pteronyssinus - stungulyf, dreifa
alutard sq (dog hair) stungulyf, dreifa
alk-abelló a/s - hundahár - stungulyf, dreifa
alutard sq (phleum pratense) stungulyf, dreifa
alk-abelló a/s - phleum pratense - stungulyf, dreifa
remurel (brabio 20 mg/ml stungulyf, lausn í áfylltri sprautu) stungulyf, lausn í áfylltri sprautu 20 mg/ml
zentiva k.s.* - glatiramer acetat - stungulyf, lausn í áfylltri sprautu - 20 mg/ml
remurel stungulyf, lausn í áfylltri sprautu 40 mg/ml
zentiva k.s.* - glatiramer acetat - stungulyf, lausn í áfylltri sprautu - 40 mg/ml
ebglyss
almirall, s.a. - lebrikizumab - dermatitis, atópísk - aðrar húðsjúkdómar - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.